The biotechnology sector is currently at a critical crossroads, marked by significant technological advances and persistent structural challenges. The "patent cliff," which threatens to reduce industry revenues by $400 billion, continues to force companies to innovate rapidly. At the same time, the integration of artificial intelligence (AI) into research and development (R&D) processes is emerging as an essential solution to maintain competitiveness. Recent initiatives, such as the launch of Anthropic's Claude Science, an AI tool for scientific research, illustrate the transformative potential of these technologies. However, these advances also raise security and ethical concerns, particularly regarding intellectual property and cyber risks.